Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
| dc.contributor.author | Waddell, T | |
| dc.contributor.author | Chau, I | |
| dc.contributor.author | Cunningham, D | |
| dc.contributor.author | Gonzalez, D | |
| dc.contributor.author | Frances, A | |
| dc.contributor.author | Okines, C | |
| dc.contributor.author | Wotherspoon, A | |
| dc.contributor.author | Saffery, C | |
| dc.contributor.author | Middleton, G | |
| dc.contributor.author | Wadsley, J | |
| dc.contributor.author | Ferry, D | |
| dc.contributor.author | Mansoor, Was | |
| dc.contributor.author | Crosby, T | |
| dc.contributor.author | Coxon, F | |
| dc.contributor.author | Smith, D | |
| dc.contributor.author | Waters, J | |
| dc.contributor.author | Iveson, T | |
| dc.contributor.author | Falk, S | |
| dc.contributor.author | Slater, S | |
| dc.contributor.author | Peckitt, C | |
| dc.contributor.author | Barbachano, Y | |
| dc.date.accessioned | 2013-07-08T15:06:13Z | |
| dc.date.available | 2013-07-08T15:06:13Z | |
| dc.date.issued | 2013-05 | |
| dc.identifier.citation | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. 2013, 14 (6):481-9 Lancet Oncol | en_GB |
| dc.identifier.issn | 1474-5488 | |
| dc.identifier.pmid | 23594787 | |
| dc.identifier.doi | 10.1016/S1470-2045(13)70096-2 | |
| dc.identifier.uri | http://hdl.handle.net/10541/295490 | |
| dc.description.abstract | EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to The lancet oncology | en_GB |
| dc.title | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. | en |
| dc.type | Article | en |
| dc.contributor.department | The Royal Marsden NHS Foundation Trust, London and Surrey, UK. | en_GB |
| dc.identifier.journal | The Lancet Oncology | en_GB |
| html.description.abstract | EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma. |